Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967430 | 1.00 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL22967504 | 1.00 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL22967478 | 0.85 | — | — | |
| SCHEMBL22967484 | 0.85 | — | — | |
| SCHEMBL22967488 | 0.85 | — | — | |
| SCHEMBL23178908 | 0.83 | KRAS (0.35) | KRAS | |
| SCHEMBL22967641 | 0.82 | KRAS (0.37) | KRAS | |
| SCHEMBL22967639 | 0.82 | KRAS (0.30) | KRAS | |
| SCHEMBL24854345 | 0.82 | KRAS (0.37) | KRAS | |
| SCHEMBL24543362 | 0.82 | KRAS (0.35) | KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002345-A1 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 782/4885 |
| US-20230002345-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 782/4885 |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | KRAS 1/4885SOS1 102/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | KRAS 1/4885SOS1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.